{{citation style|time=2018-04-29T02:38:58+00:00}}
{{expert|time=2017-12-16T18:51:16+00:00}}
{{noteTA
|G1 = Medicine
|T = zh-hant:哌甲酯; zh-cn:哌甲酯 ; zh-tw:派醋甲酯 ; zh-hk:哌甲酯; zh-sg:哌甲酯 ;
|1 = zh-hant:哌甲酯 ; zh-cn:哌甲酯 ; zh-tw:派醋甲酯 ; zh-hk:哌甲酯 ; zh-sg:哌甲酯 ;
}}
{{medical}}
{{Infobox drug
| Watchedfields = changed
| verifiedrevid = 464371569
| IUPAC_name = methyl 2-phenyl-2-(piperidin-2-yl)acetate
| image = Methylphenidate-2D-skeletal.svg
| width = 200
| image2 = Methylphenidate-enantiomers-3D-balls.png
| width2 = 225
| drug_name=派醋甲酯
| synonyms = 哌甲酯 、Methylphenidate
| caption=派醋甲酯 （Methylphenidate）的[[結構式|化學結構式]]

<!--Clinical data-->
| tradename = Concerta, Methylin, Ritalin, Medikinet, Equasym XL, Quillivant XR, Metadate, Ritalin LA, Ritalin SR, Apo-Methylphenidate
| Drugs.com = {{drugs.com|monograph|methylphenidate-hydrochloride}}
| MedlinePlus = a682188
| licence_US = Methylphenidate
| pregnancy_AU = B3
| pregnancy_US = C
| legal_AU = S8
| legal_CA = Schedule III
| legal_UK = Class B
| legal_US = Schedule II
| legal_status = Rx-only
| dependency_liability = 生理: 無<br />心理: 中
| addiction_liability = 中
| routes_of_administration = 口服, 噴霧,靜脈, 經皮

<!--Pharmacokinetic data-->
| bioavailability = ~30% (範圍: 11–52%)
| protein_bound = 10–33%
| metabolism = [[肝臟|肝臟]] (80%)
| elimination_half-life = 2–3 小时<ref name="pmid10628897">{{cite journal|last1=Kimko|first1=HC|last2=Cross|first2=JT|last3=Abernethy|first3=DR|title=Pharmacokinetics and clinical effectiveness of methylphenidate.|journal=Clinical pharmacokinetics|date=December 1999|volume=37|issue=6|pages=457–70|pmid=10628897|doi=10.2165/00003088-199937060-00002}}</ref>
| excretion = [[尿液|尿液]] (90%)

<!--Identifiers-->
| IUPHAR_ligand = 7236
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 113-45-1
| ATC_prefix = N06
| ATC_suffix = BA04
| PubChem = 4158
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00422
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4015
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 207ZZ9QZ49
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04999
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 6887
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 796

<!--Chemical data-->
| C=14 | H=19 | N=1 | O=2
| molecular_weight = 233.31 g/mol
| smiles = O=C(OC)C(C1CCCCN1)C2=CC=CC=C2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = DUGOZIWVEXMGBE-UHFFFAOYSA-N
| melting_point = 74
| melting_notes = <ref name="Pubchem properties">{{cite encyclopedia|title=Methylphenidate
|section-url=http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=4158#x27
|website=Pubchem Compound|publisher=National Center for Biotechnology Information
|accessdate=24 June 2014
|section=Chemical and Physical Properties}}</ref>
| boiling_point = 136
| boiling_notes = <ref name="Pubchem properties" />
}}

'''哌甲酯'''（英文：Methylphenidate），最常見的商品名為'''利他能'''（{{lang-en|Ritalin}}），是一種[[興奮劑|中樞神經系統興奮劑]]，被廣泛應用於[[注意力不足過動症|注意力不足過動症]]（ADHD）和[[嗜睡症|嗜睡症]]的治療。

哌甲酯的[[最簡式|化學最簡式]]為{{化學式|C|14|H|19|N|O|2}}•{{化學式|H|Cl}}。  Methylphenidate hydrochloride USP 是一種白色、無味的[[結晶|結晶]]體。哌甲酯的[[水溶液|水溶液]]介於[[酸性|酸性]]於[[鹼性|鹼性]]之間。哌甲酯能在[[純水|純水]]及[[甲醇|甲醇]]中完全溶解；在[[乙醇|乙醇]]中部分溶解；些微溶解於[[氯仿|氯仿]]和[[丙酮|丙酮]]中。Methylphenidate hydrochloride USP的[[分子量|分子量]]為269.77。<ref name="intro for methylphenidate shown on Ritalin's label">{{cite web
 | url =https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0bf0835-6a2f-4067-a158-8b86c4b0668a
 | title =Label of Ritalin
 | date =January 5, 2017
 | website = DailyMed
 | publisher =Novartis
 | access-date =March, 2017.
 | quote=Methylphenidate hydrochloride USP is a white, odorless, fine crystalline powder. Its solutions are acid to litmus. It is freely soluble in water and in methanol, soluble in alcohol, and slightly soluble in chloroform and in acetone. Its molecular weight is 269.77. }}</ref>

哌甲酯在1948年由[[CIBA|CIBA]]（後被[[諾華公司|諾華公司]]收購）研制，被用於治療注意力不足過動症而在1955年獲得[[FDA|FDA]]的銷售許可，並在之後的幾十年内成為醫治該症的臨床第一線藥物。<ref>www.ehow.com/about_5374709_ritalin-invented.html When Was Ritalin Invented?, citing Lawrence Diller: "Running on Ritalin", 1999</ref>

哌甲酯用于於醫療始於1960年。自20世紀90年代起，大眾逐漸接受ADHD的診斷，於是此藥物的處方日益增加。在2007-2012年間，英國的哌甲酯處方增加了50%。<ref>
{{Cite book
|isbn=978-0553379068
|first=Lawrence 
|last=Diller
|title=Running on Ritalin
|year= 1999}}</ref><ref>
{{cite journal |vauthors=Lange KW, Reichl S, Lange KM, Tucha L, Tucha O | title = The history of attention deficit hyperactivity disorder | journal = ADHD Attention Deficit and Hyperactivity Disorders | volume = 2 | issue = 4 | pages = 241–55 | year = 2010 | pmid = 21258430 | pmc = 3000907 | doi = 10.1007/s12402-010-0045-8 }}</ref>在2013年，全球的哌甲酯銷售量增加到了24億劑，與前一年同比上升66%。美國的消費量占全球的80%以上。 <ref>{{cite web|url=http://www.bbc.com/news/health-23674235|title=ADHD drug use 'up 50% in six years'|date=2013-08-13|publisher=|via=www.bbc.com}}</ref><ref>{{cite web|url=http://www.pharmaceutical-journal.com/news-and-analysis/news-in-brief/narcotics-monitoring-board-reports-66-increase-in-global-consumption-of-methylphenidate/20068042.article|title=Narcotics monitoring board reports 66% increase in global consumption of methylphenidate|publisher=}}</ref>

注意力不足過動症的病因可能與[[多巴胺|多巴胺]]、[[去甲腎上腺素|去甲腎上腺素]]和[[穀氨酸|穀氨酸]]有關。這些物質决定了大腦的自我約束功能，並影響個人的[[注意力|注意力]]、控制力、[[行為|行為]]、[[動機|動機]]和執行能力。哌甲酯的作用便是抑制去甲腎上腺素和多巴胺的再回收，使這些[[神經傳遞物質|神經傳遞物質]]的濃度和强度大幅提高。哌甲酯和[[古柯鹼|古柯鹼]]在結構和藥理上有相似之處，但哌甲酯的效力低於後者，藥效長於後者。<ref>[http://learn.genetics.utah.edu/content/addiction/issues/ritalin.html "Ritalin & Cocaine: The Connection and the Controversy"] {{Wayback|url=http://learn.genetics.utah.edu/content/addiction/issues/ritalin.html |date=20130121210239 }}. Learn.genetics.utah.edu. Retrieved on 2011-10-16.</ref><ref>
{{cite book
|author=Mary Ann Boyd
|title=Psychiatric nursing: contemporary practice
|url=http://books.google.com/books?id=a-GcGVtBnqQC&pg=PA160
|accessdate=30 April 2011
|year=2005
|publisher=Lippincott Williams & Wilkins
|isbn=978-0-7817-4916-9
|pages=160–}}</ref><ref>
{{cite journal 
|url=http://www.neuropsychiatryreviews.com/feb02/adictive.html 
|archiveurl=https://web.archive.org/web/20090330105926/http://www.neuropsychiatryreviews.com/feb02/adictive.html 
|archivedate=2009-03-30 
|title=Why isn't methylphenidate more addictive? 
|journal=NeuroPsychiatry Rev. 
|year=2002 
|author=Peter Doskoch 
|volume=3 
|issue=1 
|page=19 
|access-date=2013-01-24 
|dead-url=yes 
}}
</ref><ref name='cortex'>
{{cite web 
| url = http://www.medscape.org/viewarticle/523887_4 
| title = Functional Roles of Norepinephrine and Dopamine in ADHD: Dopamine in ADHD 
| accessdate = 8 October 2013 
| year = 2006 
| work = Medscape
|quote=Catecholamines not only facilitate attention, they are essential to executive function. The prefrontal cortex directs behaviors, thoughts, and feelings represented in working memory. This representational knowledge is essential to fundamental cognitive abilities that compromise executive functions. These encompass the ability to (1) inhibit inappropriate behaviors and thoughts, (2) regulate our attention, (3) monitor our actions, and (4) plan and organize for the future. Difficulties with these prefrontal cortex functions are evident in neuropsychological and imaging studies of ADHD patients and account for many of the common behavioral symptoms. Measures of prefrontal cortical functioning in animals indicate that these functions are sensitive to small changes in catecholamine modulation of prefrontal cortex cells that can produce profound effects on the ability of the prefrontal cortex to guide behavior. Optimal levels of NE acting at postsynaptic alpha2A-adrenoceptors and dopamine acting at D1 receptors are essential to prefrontal cortex function. Blockade of norepinephrine alpha2-adrenoceptors in prefrontal cortex markedly impairs prefrontal cortex function and mimics most of the symptoms of ADHD, including impulsivity and locomotor hyperactivity. Conversely, stimulation of prefrontal cortical alpha2-adrenoceptors strengthens prefrontal cortex regulation of behavior and reduces distractibility. Thus, effective treatments for ADHD facilitate catecholamine transmission and apparently have their therapeutic actions by optimizing catecholamine actions in the prefrontal cortex}}</ref><ref>
{{cite journal 
|vauthors=Arnsten AF, Li BM 
| title = Neurobiology of Executive Functions: Catecholamine Influences on Prefrontal Cortical Functions 
| journal = Biological Psychiatry 
| volume = 57 
| issue = 11 
| pages = 1377–84 
| year = 2005 
| pmid = 15950011 
| doi = 10.1016/j.biopsych.2004.08.019 }}</ref>哌甲酯也是一種較弱的{{tsl|en|5-HT1A receptor|5-HT1A受體|5HT<sub>1A</sub>}}受體興奮劑。<ref>
{{cite journal 
|pmid=19322953 
| volume=64 
| title=The psychostimulant d-threo-(R,R)-methylphenidate binds as an agonist to the 5HT(1A) receptor.
| date=Feb 2009 
| journal=Pharmazie 
| pages=123–5 
| author=Markowitz JS, DeVane CL, Ramamoorthy S, Zhu HJ}}</ref>

這一藥品在全球範圍内基本都受到不同程度的管制。

整體而言，哌甲酯與同為中樞神經興奮劑的[[安非他命|安非他命]]結構上相似，但哌甲酯和安非他命不同，不容易造成成癮。用藥者應詳閱並遵照藥品說明書的指引。

== 用途 ==

=== 醫療用途 ===
哌甲酯是一種常見的興奮劑類物，藥理是阻斷去甲腎上腺素和多巴胺的回收。它所能產生的效果包括增加並維持警惕性、抵抗疲勞與提升注意力。哌甲酯的短期效益與成本效益已經確立。哌甲酯未被許可用於6歲以下的兒童。哌甲酯也可能用於治療非適應症，例如[[躁鬱症|躁郁症]]與[[重度鬱鬱症|重度鬱鬱症]]。

核磁共振的元分析與系統綜述表明，長期使用ADHD興奮劑（特别是安非他命與哌甲酯）可以減少ADHD受試者的大腦中的結構異常與功能異常。此外，臨床興奮劑研究的評論已確定了長期連續使用ADHD興奮劑對ADHD患者的安全性與有效性，長期所指的時間長達數年。然而，截至2015年11月，哌甲酯對患者的ADHD症狀與生活質量的改善的精確度仍不明確。

==== [[注意力不足過動症|注意力不足過動症]] ====
{{main article|注意力不足過動症}}
哌甲酯被[[美國食品藥品監督管理局|美国食品与药品监督管理局]]（FDA）批准用治療注意力不足過動症。與{{En-link|行為修正|Behavior modification}}與[[認知行為療法|認知行為療法]]配合治療效果更佳。藥物劑量的個體差異很大，因此使用的劑量必須精確。

ADHD當前的病理模型表明，ADHD與大腦中部分[[神經傳遞物質|神經傳遞物質]]系統（尤其是涉及[[多巴胺|多巴胺]]與[[去甲腎上腺素|去甲腎上腺素]]的）中的功能障礙有關。哌甲酯与安非他命这一类的精神兴奋剂能够增加这些系统中的神经递质地活性，因而可能有效地治疗ADHD。约70%的使用者能改善ADHD的症状。使用哌甲酯的ADHD患儿通常能与同龄人与家庭成员建立更好的关系，在学校表现更好，且更少分心或冲动，能保持更久的注意力。ADHD患者的[[物質使用疾患|药物滥用失常]]可能性增加，而刺激性药物能降低这种风险。

==== [[嗜睡症|嗜睡症]] ====
嗜睡症是一种慢性睡眠障碍，会导致在白天难以抑制的困倦，以及突然产生的困意，主要需要兴奋剂予以治疗。哌甲酯被认为有助于提升觉醒度、警惕性与行为表现。哌甲酯能改善标准化测试中嗜睡的结果，如{{En-link|多重睡眠潜伏期试验|Multiple Sleep Latency Test}}，但是不能提升到正常人的水平。

==== 其他 ====
哌甲酯也可能用于治疗[[重性抑郁障碍|重性抑郁障碍]]。它可以降低中风、癌症与HIV阳性患者的抑郁水平。然而，用兴奋剂治疗耐受性抑郁症的做法具有争议。在老人与病人身上，兴奋剂可能比[[三环类抗抑郁药|三环类抗抑郁药]]具有更少的副作用。对于癌症晚期患者，哌甲酯可用于抵抗鸦片类药物导致的嗜睡，治疗抑郁症与改善认知功能。

=== 增强行为表现([[益智藥|益智藥]]) ===
2015年，对高质量临床试验进行的[[元分析|荟萃分析]]与[[系統綜述|系统评价]]中发现，对于健康成人而言，治疗剂量的苯丙胺与哌甲酯可以造成认知能力（包括[[工作记忆|工作记忆]]、[[情节记忆|情景记忆]]和[[抑制控制试验|抑制控制试验]]）轻微但明确的改善，其作用机制为间接激活前额叶皮层的多巴胺受体D<sub>1</sub>与肾上腺皮质受体α2。哌甲酯与其他ADHD兴奋剂也可以提升任务的突出性与增强唤起。哌甲酯通过[[再攝取抑制劑|抑制再摄取]]中枢神经系统中的多巴胺来增加人的耐力与专注度。安非他命与哌甲酯这一类药物可以提升在执行枯燥与困难任务时的表现，并被某些学生用于学习与考试的辅助。基于自我报告的对兴奋剂违规使用的调查研究显示，提升表现而非用于娱乐，是学生使用兴奋剂的主要原因。与安非他命和安非他命酮类似，高于治疗剂量的哌甲酯可能对工作记忆与[[管控功能|管控能力]]有负面影响，同时大剂量的哌甲酯还可能损害运动能力，如导致[[横纹肌溶解症|横纹肌溶解症]]与中暑。

==== 增强行为表现的道德问题 ====
哌甲酯有时被学生用来增强其精神能力，帮助集中注意力与帮助学习。

生物伦理学专家{{En-link|约翰·哈里斯|John Harris}}认为，阻止健康人服用这种药物是不道德的。

他指出，如果人们可以接受一所大学“专门提升学生的精神能力，保证学生毕业时更加聪明，还能让它的学生比历史上任何学生都更聪敏”，并且为之高兴且都想把孩子送去的话，为什么在当下出现了这么一种“安全的、可以提升认知能力的药物”时，用药就成了不道德的呢？他提出阻止用药反而不道德。他声明称反对使用药物提升人类认知力是“不理性的”，且阻止了人类的发展。

Barbara Sahakian称这种使用利他林的方式可能导致学生在考试中拥有不公平的优势，最终导致大学可能会考虑要求学生提供尿样以进行药物检测。

== 禁忌症 ==
以下情况禁用哌甲酯：
* 使用[[单胺氧化酶抑制剂|单胺氧化酶抑制剂]]（如苯乙肼、[[反苯环丙胺|反苯环丙胺]]）时
* 有激越、[[抽动综合症|抽动综合症]]、[[青光眼|青光眼]]等情况
* 对哌甲酯药物中任何成分有超敏反应
美国FDA对哌甲酯的怀孕分级为C，建议女性只在效用超过潜在风险时使用。还没有足够的动物实验和人类研究足以说明哌甲酯对胎儿发育的作用。至2007年，实证文献中共包含来自3个实证研究的63条产前接触哌甲酯的案例。

==药理學==

=== [[药效学|药效学]] ===
{| class="wikitable" style="float:right;margin-left:5px; text-align:center"
|+Binding profile（{{tsl|en|Binding Affinity}}）<ref name=pmid18480678>{{cite journal|last1=Markowitz|first1=JS|last2=Patrick|first2=KS|title=Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter?|journal=Journal of Clinical Psychopharmacology|date=June 2008|volume=28|issue=3 Suppl 2|pages=S54-61|doi=10.1097/JCP.0b013e3181733560|pmid=18480678}}</ref><ref name=pmid17218796>{{cite journal|last1=Williard|first1=RL|last2=Middaugh|first2=LD|last3=Zhu|first3=HJ|last4=Patrick|first4=KS|title=Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity.|journal=Behavioural Pharmacology|date=February 2007|volume=18|issue=1|pages=39–51|pmid=17218796|doi=10.1097/fbp.0b013e3280143226}}</ref><ref name=pmid17201613>{{cite journal|last1=Markowitz|first1=JS|last2=DeVane|first2=CL|last3=Pestreich|first3=LK|last4=Patrick|first4=KS|last5=Muniz|first5=R|title=A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study.|journal=Journal of child and adolescent psychopharmacology|date=December 2006|volume=16|issue=6|pages=687–98|pmid=17201613|doi=10.1089/cap.2006.16.687}}</ref>
|-
! {{tsl|en|Neurotransmitter transporter|Neurotransmitter transporter|Neurotransmitter<br />transporter}}
! Measure<br />(units)
! {{abbr|dl-MPH|d,l-threo-methylphenidate or racemic methylphenidate}}
! {{abbr|d-MPH|d-threo-methylphenidate or dexmethylphenidate}}
! {{abbr|l-MPH|l-threo-methylphenidate or levomethylphenidate}}
|- 
| rowspan="2" | [[Dopamine_transporter|DAT]]
| [[Dissociation_constant|K<sub>i</sub>]] ({{abbrlink|nM|nanomolar}})
| 121
| 161
| 2250
|-
| {{tsl|en|IC50|IC50|IC<sub>50</sub>}} ({{abbr|nM|nanomolar}})
| 20
| 23
| 1600
|- 
| rowspan="2" | [[Norepinephrine_transporter|NET]]
| K<sub>i</sub> (nM)
| 788
| 206
| >10000
|- 
| IC<sub>50</sub> (nM)
| 51
| 39
| 980
|-
| rowspan="2" | [[Serotonin_transporter|SERT]]
| K<sub>i</sub> (nM)
| >10000
| >10000
| >6700
|-
| IC<sub>50</sub> (nM)
| style="text-align:center;" | <nowiki>—</nowiki>
| >10000
| >10000
|-
! [[GPCR|GPCR]]
! Measure<br />(units)
! {{abbr|dl-MPH|d,l-threo-methylphenidate or racemic methylphenidate}}
! {{abbr|d-MPH|d-threo-methylphenidate or dexmethylphenidate}}
! {{abbr|l-MPH|l-threo-methylphenidate or levomethylphenidate}}
|-
| rowspan="2" | {{tsl|en|5-HT1A receptor|5-HT1A receptor|5-HT<sub>1A</sub>}}
| K<sub>i</sub> ({{abbrlink|nM|nanomolar}})
| 5000
| 3400
| >10000
|-
| IC<sub>50</sub> ({{abbr|nM|nanomolar}})
| 10000
| 6800
| >10000
|-
| rowspan="2" | [[5-HT2B_receptor|5-HT<sub>2B</sub>]]
| K<sub>i</sub> (nM)
| >10000
| 4700
| >10000
|-
| IC<sub>50</sub> (nM)
| >10000
| 4900
| >10000
|}

哌甲酯是一种苯哌啶衍生物。它与儿茶酚胺和苯乙胺有相同的基本结构。

哌甲酯主要充当[[去甲腎上腺素-多巴胺再攝取抑制劑|去甲腎上腺素-多巴胺再攝取抑制劑]](NDRI)，一般有调整多巴胺水平在较小程度上也影响去甲肾上腺素的作用。<ref name="Heal DJ, Pierce DM 2006 713–38">{{Cite journal|author=Heal DJ, Pierce DM |title=Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system |journal=CNS Drugs |volume=20 |issue=9 |pages=713–38 |year=2006 |pmid=16953648 |doi= 10.2165/00023210-200620090-00002 }}</ref> 与[[古柯碱|古柯碱]]相似，哌甲酯与[[多巴胺运转体|多巴胺运转体]](DAT)和[[去甲肾上腺素运转体|去甲肾上腺素运转体]](NET)结合并抑制其作用。<ref>{{Cite journal|author=Iversen L |title=Neurotransmitter transporters and their impact on the development of psychopharmacology |journal=British Journal of Pharmacology |volume=147 |issue=Suppl 1 |pages=S82–8 |year=2006 |pmid=16402124 |pmc=1760736 |doi=10.1038/sj.bjp.0706428}}</ref>

[[File:哌甲酯的神经作用.png|357×248px]]

此外，哌甲酯被认为是一种释放剂，通过提升多巴胺和去甲肾上腺素的释放，但作用不及[[安非他命|安非他命]]。<ref name="pmid15955613">{{Cite journal|author=Sulzer D, Sonders MS, Poulsen NW, Galli A |title=Mechanisms of neurotransmitter release by amphetamines: a review |journal=Prog. Neurobiol. |volume=75 |issue=6 |pages=406–33 |year=2005 |pmid=15955613 |doi=10.1016/j.pneurobio.2005.04.003 |url=http://www.sulzerlab.org/pdf_articles/Sulzer05AMPHreview.pdf |format=PDF}}</ref> 哌甲酯的作用机理被广泛争论，但和安非他命相比，它被认为加速了放电速率，而安非他命逆转了单胺运转体的流动。<ref name="pmid15303308">{{Cite journal|author=Viggiano D, Vallone D, Sadile A |title=Dysfunctions in dopamine systems and ADHD: evidence from animals and modeling |journal=Neural Plasticity |volume=11 |issue=1–2 |pages=102, 106–107 |year=2004 |pmid=15303308 |pmc=2565441 |doi=10.1155/NP.2004.97}}Full-text [http://downloads.hindawi.com/journals/np/2004/484192.pdf]</ref><ref>Novartis: [https://www.medportica.com/medporticaPortal/microsite.portal?microsite_product_name=FOCALIN Focalin XR Overview]{{Dead link|date=2019年4月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref><ref>[http://www.pharma.us.novartis.com/product/pi/pdf/focalinXR.pdf Focalin XR – Full Prescribing Information]. Novartis.</ref><ref>[http://www.medicines.org.uk/emc/medicine/8382/SPC/Concerta#PHARMACOLOGICAL_PROPS SPC Concerta XL 18 mg – 36 mg prolonged release tablets] last updated on the eMC: 05/11/2010</ref> 虽然两者作用都与多巴胺有关，但作用的方式明显不同。具体而言，哌甲酯是一种多巴胺再摄取抑制剂，而安非他命是一种促多巴胺释放剂。两者都对去甲肾上腺素有相应的微小作用。

哌甲酯具有多巴胺运转体和去甲肾上腺素运转体的亲和力，它的右旋对映体对去甲肾上腺素运转体显示了强烈的亲合势。左右两种对映体都显示了对5HT<sub>1A</sub>和5HT<sub>2B</sub>子类型的[[5-羟色胺受体|5-羟色胺受体]]的亲和力，尽管没有观察到和[[5-羟色胺转运体|5-羟色胺转运体]]直接的结合。<ref name="pmid17201613">{{Cite journal|author=Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R |title=A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study |journal=J Child Adolesc Psychopharmacol |volume=16 |issue=6 |pages=687–98 |year=2006 |pmid=17201613 |doi=10.1089/cap.2006.16.687 }}</ref>

哌甲酯可能也会产生保护神经的作用。<ref name="neuroprotection">{{Cite journal|author=T. J. Volz |title=Neuropharmacological Mechanisms Underlying the Neuroprotective Effects of Methylphenidate |journal=Current Neuropharmacology |year=2008 |pmid=  |pmc=2701286 |doi=10.2174/157015908787386041 |url=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2701286}}</ref>

右旋对映体比左旋对映体效果甚佳<ref name="Heal DJ, Pierce DM 2006 713–38" />，所以一些药物仅含有哌甲酯的右旋对映体。{{citation needed|date=January 2013}}

=== 药物代謝动力学 ===
口服哌甲酯能达到11-52%的生物利用度，一次性释放（如利他林）其峰值效果能持续2-4小时，而缓释（如利他林SR）可持续3-8小时，或延长释放片剂可持续8-12小时（如Concerta）。哌甲酯的半衰期为2-3小时，取决于个体，服药约2小时后血浆浓度达到峰值。

口服给药时，哌甲酯的右旋同分异构体的生物利用度比其左旋同分异构体更高，且是哌甲酯[[外消旋混合物|外消旋混合物]]中起精神活性作用的主要物质。

与预计相反，在餐中服用哌甲酯可加快吸收。

哌甲酯在{{En-link|羧酸酯酶1|Carboxylesterase 1}}的作用下代谢为{{En-link|利他林酸|EditWatch this page Ritalinic acid}}。右旋体与左旋体相比代谢速度更慢。

==副作用==
哌甲酯通常有高的耐受量。

观察到最常见的副作用包括食欲不振、口干、焦虑/紧张、恶心与失眠。

胃肠道的不良反应可包括腹部疼痛和体重减轻。

神经系统的副作用可包括坐立不安、易怒、{{En-link|运动障碍|Dyskinesia}}、困倦和头晕。

心脏的不良反应可包括心悸、血压变化、心率变化和[[心跳过速|心跳过速]]。

眼科方面的不良反应可能包括视力模糊和干眼，罕见复视与瞳孔扩大。

其他的副作用可能包括抑郁、情绪不稳、神志不清和磨牙。常见多汗，罕见胸痛。

有部分证据表明长期用药的儿童出现了略微的生长速度下降，但没有发现因果关系，且下降的情况没有长期存在。[[超敏反應|超敏反应]]（包括[[疹|皮疹]]、[[荨麻疹|荨麻疹]]和发烧）时有报道。

哌甲酯可以使精神病患者的精神病恶化，且在非常罕见的情况下可导致新的精神病症状的出现。由于此药物对狂躁与[[轻度狂躁|轻度狂躁]]有潜在的诱发性，在用于[[躁鬱症|躁郁症]]患者时应特别小心。

有非常罕见的引发自杀念头的报道，但不足以建立因果联系。

偶尔有出血的报告。很少有导致性欲障碍、定向力障碍与幻觉的报道。[[陰莖異常勃起|阴茎异常勃起]]是其可能导致的非常罕见但可能严重的不良反应。

2011年，由FDA委托的研究表明，在儿童与成人中，哌甲酯或其他ADHD兴奋剂的医疗用途不会导致严重不良心血管事件（猝死，心脏病发作和中风）。

部分不良反应只在长期使用哌甲酯时出现，故应留意用药期间出现的不良反应。<ref>{{Cite journal|author=Gordon N |title=Attention deficit hyperactivity disorder: possible causes and treatment |journal=Int. J. Clin. Pract. |volume=53 |issue=7 |pages=524–8 |year=1999 |pmid=10692738 }}</ref><ref>{{Cite journal |author=King S, Griffin S, Hodges Z, ''et al.'' |title=A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents |journal=Health Technol Assess |volume=10 |issue=23 |pages=iii–iv, xiii–146 |year=2006 |pmid=16796929 |url=http://www.hta.ac.uk/execsumm/summ1023.htm |access-date=2013-01-21 |archive-url=https://archive.is/20120802130417/http://www.hta.ac.uk/execsumm/summ1023.htm |archive-date=2012-08-02 |dead-url=yes }}</ref><ref>{{Cite journal|author=Gonzalez de Dios J, Cardó E, Servera M |title=[Methylphenidate in the treatment of attention-deficit/hyperactivity disorder: are we achieving an adequate clinical practice?] |language=Spanish; Castilian |journal=Rev Neurol |volume=43 |issue=12 |pages=705–14 |year=2006 |pmid=17160919 }}</ref>

其他的副作用包括：<ref>[http://www.drugs.com/sfx/ritalin-side-effects.html – Ritalin Side Effects]. Drugs.com. Retrieved on 2011-10-16.</ref>

{{columns-list|2|
*[[腹痛|腹痛]]
*失静症 (烦躁不安)
*[[脱发|脱发]]
*暴躁
*[[心绞痛|心绞痛]]
*[[厌食症|厌食症]]
*[[焦虑|焦虑]]
*[[血压|血压]]和[[脉搏|脉搏]]变化 (上升和下降皆有可能)
*[[心律不整|心律不整]]
*[[憂鬱|憂鬱]]
*[[出汗|出汗]]
*[[眩暈_(醫學)|眩晕]]
*运动障碍
*欣快或烦躁不安
*[[头痛|头痛]]
*[[过敏|过敏]] (包括[[皮疹|皮疹]], [[荨麻疹|荨麻疹]], [[发热|发热]], 关节痛, 剥脱性皮炎, 多形性红斑, 坏死性脉管炎,和血小板减少性紫癜)
*[[倦怠|倦怠]]
*性欲变化
*反胃
*[[心悸|心悸]]
*瞳孔放大<ref>{{Cite journal|author=Jaanus SD |title=Ocular side-effects of selected systemic drugs |journal=Optom Clin |volume=2 |issue=4 |pages=73–96 |year=1992 |pmid=1363080 }}</ref>
*精神失常<ref>{{Cite journal|author=Auger RR, Goodman SH, Silber MH, Krahn LE, Pankratz VS, Slocumb NL |title=Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: a case-control study |journal=Sleep |volume=28 |issue=6 |pages=667–72 |year=2005 |pmid=16477952 }}</ref>
*暂时性体重减少
*[[失眠|失眠]]
*生长萎缩
*自杀倾向
*口腔干燥
}}

== 滥用 ==
哌甲酯急性过量的症状主要是因为中枢神经系统受到过度刺激。这些症状包括：呕吐、焦虑、震颤、{{En-link|反射亢进|Hyperreflexia}}、肌肉抽搐、[[欣快|欣快]]、幻觉、[[譫妄|谵妄]]、中暑、出汗、潮红、头痛、[[心跳过速|心跳过速]]、[[心律失常|心律失常]]、[[心悸|心悸]]、[[高血壓|高血压]]、瞳孔扩大和[[黏膜|黏膜]]干燥。

严重的过量可能导致高热（不低于41.5℃）、肾上腺素过多、[[驚厥|惊厥]]、[[偏執狂|偏执]]、{{En-link|刻板症|Stereotypy}}、快速肌肉衰竭（[[横纹肌溶解症|横纹肌溶解症]]）、[[昏迷|昏迷]]和{{En-link|循环衰竭|Circulatory collapse}}。

有将哌甲酯片剂注射入动脉后导致[[膿瘍|脓肿]]和[[坏死|坏死]]的毒性反应的报道。

如果予以适当的救助，哌甲酯过量很少致命。

=== 成瘾性与依赖性 ===
药理学文章认为哌甲酯是一种效果、成瘾性、依赖性与[[苯丙胺|苯丙胺]]（安非他命）类似的兴奋剂，而[[苯丙胺|苯丙胺]]在可成瘾药物中处于中等。因此，当把哌甲酯高剂量使用作为娱乐性药物时，成瘾与心理依赖是可能的。当使用剂量大于医用剂量时，兴奋剂与{{En-link|兴奋剂型精神病|Stimulant psychosis}}的发展产生关联。与所有有成瘾性的药物一样，其成瘾机制为[[ΔFosB|ΔFosB]]在[[伏隔核|伏隔核]]中的{{En-link|D1型|D1-like_receptor}}[[中等有棘神经元|中等有棘神经元]]中过量表达。

哌甲酯作为一种戒除[[甲基苯甲胺|甲基苯甲胺]]成瘾过程中的替代物质时表现出了一些好的效果。哌甲酯和安非他命已被研究作为[[可卡因|可卡因]]成瘾治疗中的化学替代品，[[美沙酮|美沙酮]]也被以同样的方式用作替代药物治疗对[[海洛因|海洛因]]的生理依赖。其在治疗可卡因或心理/生理成瘾方面的作用尚未证实，还有待进一步研究。

==== 生物分子机制 ====
因为哌甲酯在大脑的[[奖赏系统|奖赏系统]]中的[[药物效应动力学|药物效应动力学]]作用（抑制多巴胺再摄取），其具有导致[[欣快|欣快]]的潜力。在治疗剂量下，ADHD兴奋剂不会充分激活奖赏系统，或者{{En-link|奖赏路径|Mesolimbic pathway}}，以引起[[ΔFosB|ΔFosB]]基因在[[伏隔核|伏隔核]]中的{{En-link|D1型|D1-like_receptor}}[[中等有棘神经元|中等有棘神经元]]中持久表达。因此，当用于医疗且遵照医嘱时，哌甲酯不会成瘾。然而，当哌甲酯以足够高的剂量通过高生物利用度的给药途径（如吸入或静脉注射）使用，尤其是用作兴奋剂时，[[ΔFosB|ΔFosB]]会在[[伏隔核|伏隔核]]中积累。因此，与其他可成瘾药物一样，娱乐用途的高剂量哌甲酯最终会导致[[ΔFosB|ΔFosB]]在[[伏隔核|伏隔核]]中的{{En-link|D1型|D1-like_receptor}}[[中等有棘神经元|中等有棘神经元]]中过量表达，随后引发一系列激活基因转录的[[信号转导|信号转导]]，导致上瘾。

== 交互作用 ==
哌甲酯可以抑制{{En-link|豆香素抗凝血剂|Vitamin K antagonist}}、某些抗惊厥药物和一些抗抑郁药（[[三环类抗抑郁药|三环类抗郁药]]和[[选择性5-羟色胺再摄取抑制剂|选择性5-羟色胺再摄取抑制剂]]）的代谢。共同给药可能需要调整剂量，可能需要监测血浆药物浓度来辅助。
<!-- <onlyinclude>{{#ifeq:{{{transcludesection|Interactions}}}|Interactions|
Methylphenidate may inhibit the metabolism of [[Vitamin_K_antagonist|coumarin anticoagulants]], certain [[anticonvulsants|anticonvulsants]], and some antidepressants ([[tricyclic_antidepressants|tricyclic antidepressants]] and [[selective_serotonin_reuptake_inhibitors|selective serotonin reuptake inhibitors]]). Concomitant administration may require dose adjustments, possibly assisted by monitoring of plasma drug concentrations.--><ref name="concerta_monograph">
{{cite web
|title=Concerta product monograph
|url=https://www.janssenmd.com/pdf/concerta/CONCERTA_PI.pdf
|publisher=Janssen Pharmaceuticals
|accessdate=4 December 2016}}</ref>
有几例哌甲酯与抗郁药共同使用诱发血清素综合征的案例。
<!-- There are several case reports of methylphenidate inducing [[serotonin_syndrome|serotonin syndrome]] with concomitant administration of antidepressants.<ref>
{{cite journal
| last1=Ishii
| first1=M
| last2=Tatsuzawa
| first2=Y
| last3=Yoshino
| first3=A
| last4=Nomura
| first4=S
| title=Serotonin syndrome induced by augmentation of SSRI with methylphenidate.
| journal=Psychiatry and clinical neurosciences
| date=April 2008
| volume=62
| issue=2
| pages=246
| doi=10.1111/j.1440-1819.2008.01767.x
| pmid=18412855}}</ref><ref>
{{cite journal
|　last1=Türkoğlu
|　first1=S
|　title=Serotonin syndrome with sertraline and methylphenidate in an adolescent.
|　journal=Clinical neuropharmacology
|　date=2015
|　volume=38
|　issue=2
|　pages=65–6
|　doi=10.1097/WNF.0000000000000075
|　pmid=25768857}}</ref><ref>
{{cite journal
|last1=Park
|first1=YM
|last2=Jung
|first2=YK
|title=Manic switch and serotonin syndrome induced by augmentation of paroxetine with methylphenidate in a patient with major depression.
|journal=Progress in neuro-psychopharmacology & biological psychiatry
|date=30 May 2010
|volume=34
|issue=4
|pages=719–20
|doi=10.1016/j.pnpbp.2010.03.016
|pmid=20298736}}</ref><ref>
{{cite journal
|last1=Bodner
|first1=RA
|last2=Lynch
|first2=T
|last3=Lewis
|first3=L
|last4=Kahn
|first4=D
|title=Serotonin syndrome.
|journal=Neurology
|date=February 1995
|volume=45
|issue=2
|pages=219–23
|pmid=7854515
|doi=10.1212/wnl.45.2.219}}</ref>

当哌甲酯与乙醇共存时，会通过肝中的[[酯交换反应|酯交换]]生成代谢物{{En-link|哌乙酯|Ethylphenidate}}<!--When methylphenidate is coingested with [[ethanol|ethanol]], a metabolite called [[ethylphenidate|ethylphenidate]] is formed via hepatic transesterification,<ref>{{cite journal 
| vauthors=Patrick KS, González MA, Straughn AB, Markowitz JS 
| title = New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder 
| journal = Expert Opinion on Drug Delivery 
| volume = 2 
| issue = 1 
| pages = 121–43 
| year = 2005 
| pmid = 16296740 
| doi = 10.1517/17425247.2.1.121 }}</ref><ref name="Markowitz">
{{cite journal 
| vauthors=Markowitz JS, DeVane CL, Boulton DW, Nahas Z, Risch SC, Diamond F, Patrick KS 4
| title = Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol 
| journal = Drug Metabolism and Disposition 
| volume = 28 
| issue = 6 
| pages = 620–4 
| year = 2000 
| pmid = 10820132 }}</ref>，与可卡因与酒精共用时在肝中生成{{En-link|高古柯碱|Cocaethylene}}的反反应不同。哌乙酯所减少的效力以及其微小的生成量意味着它不会影响哌甲酯的药效，无论是药用剂量还是过量，哌乙酯的浓度都可以忽略不计。
<!--not unlike the hepatic formation of [[cocaethylene|cocaethylene]] from [[Cocaine#Metabolism_and_excretion|cocaine and alcohol]]. The reduced potency of ethylyphenidate and its minor formation means it does not contribute to the pharmacological profile at therapeutic doses and even in overdose cases ethylphenidate concentrations remain negligible.--><ref name="pmid10440465">
{{cite journal 
|vauthors=Markowitz JS, Logan BK, Diamond F, Patrick KS 
| title = Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion 
| journal = Journal of Clinical Psychopharmacology 
| volume = 19 
| issue = 4 
| pages = 362–6 
| year = 1999 
| pmid = 10440465 
| doi = 10.1097/00004714-199908000-00013 }}</ref><ref name="pmid10820132">
{{cite journal 
|vauthors=Markowitz JS, DeVane CL, Boulton DW, Nahas Z, Risch SC, Diamond F, Patrick KS 
| title = Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol 
| journal = Drug metabolism and disposition: the biological fate of chemicals 
| volume = 28 
| issue = 6 
| pages = 620–4 
| year = 2000 
| pmid = 10820132 }}</ref>

与酒精的混合作用可导致d-哌甲酯的血浆浓度上升最多40%。
<!-- Coingestion of alcohol (ethanol) also increases the blood plasma levels of d-methylphenidate by up to 40%.--><ref name=pmid17339864>
{{cite journal
|vauthors=Patrick KS, Straughn AB, Minhinnett RR, Yeatts SD, Herrin AE, DeVane CL, Malcolm R, Janis GC, Markowitz JS
|title=Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics.
|journal=Clinical pharmacology and therapeutics
|date=March 2007
|volume=81
|issue=3
|pages=346–53
|pmid=17339864
|pmc=3188424
|doi=10.1038/sj.clpt.6100082}}</ref>

哌甲酯的{{En-link|肝毒性|Hepatotoxicity}}极其罕见，但有限的证据表明，与哌甲酯共同摄入{{En-link|β肾上腺素激动剂|Beta-adrenergic agonist}}可能增加肝中毒的风险。
<!-- [[Liver_toxicity|Liver toxicity]] from methylphenidate is extremely rare, but limited evidence suggests that intake of [[Beta-adrenergic_agonist|β-adrenergic agonists]] with methylphenidate may increase the risk of liver toxicity.--><ref>
{{cite journal 
| vauthors=Roberts SM, DeMott RP, James RC 
| title = Adrenergic modulation of hepatotoxicity 
| journal = Drug Metab. Rev. 
| volume = 29 
| issue = 1–2 
| pages = 329–53 
| year = 1997 
| pmid = 9187524 
| doi = 10.3109/03602539709037587 }}</ref></onlyinclude>

===v.s 阿托莫西汀===
[[Atomoxetine|阿托莫西汀]]為另一種常見用於治療注意力不足/過動症（AD/HD）的第一線藥物。

縱然阿托莫西汀與中樞神經興奮劑同樣為治療ADHD的<u>第一線藥物</u>，然而其對特定症狀改善的程度可能與中樞神經興奮劑不同（兩類藥物各有其長處）。阿托莫西汀在改善過動-衝動的症狀上，略優於派甲酯；派甲酯則在改善分心的症狀上，略優於阿托莫西汀。<ref>{{Cite journal
 | author = Chi-Yung Shang, Yi-Lei Pan, Hsiang-Yuan Lin, Lin-Wan Huang & Susan Shur-Fen Gau
 | title = An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder
 | journal = Journal of child and adolescent psychopharmacology
 | volume = 25
 | issue = 7
 | pages = 566–573
 | date = September 2015
 | doi = 10.1089/cap.2015.0035
 | pmid = 26222447
 | quote = At week 24, mean changes in ADHD-RS-IV Inattention scores were 13.58 points (Cohen's d, -3.08) for OROS-methylphenidate and 12.65 points (Cohen's d, -3.05) for atomoxetine; and mean changes in ADHD-RS-IV Hyperactivity-Impulsivity scores were 10.16 points (Cohen's d, -1.75) for OROS-methylphenidate and 10.68 points (Cohen's d, -1.87) for atomoxetine.
}}</ref><ref>{{cite web
 | archive-url =https://www.mohw.gov.tw/MOHW_Upload/doc/心理衛生專輯/03注意力不足過動症.pdf
 | archive-date=June 2015
 | title =中華民國衛生福利部/心理衛生專輯/03注意力不足過動症.pdf
 | date = June 2015
 | website = http://www.mohw.gov.tw/
 | publisher = 中華民國衛生福利部
 | access-date = February 2017
 | quote = 一般發現其對於專注度的改善沒有 MPH 明顯
 | url=https://www.mohw.gov.tw/MOHW_Upload/doc/心理衛生專輯/03注意力不足過動症.pdf}} </ref><ref>{{Citation
 | last =
 | first =
 | author-link =蔣丙煌
 | last2 =
 | first2 =
 | author2-link =陳快樂
 | author3-link=國立臺灣大學醫學院附設醫院精神醫學部
 | author4=張雍敏、鄭淑心、賴淑玲、傅悅娟、張景瑞、侯育銘、郭約瑟、張君威、鄧惠文、陳嘉新、紀雪雲、黃雅文、連玉如、連盈如、吳其炘
 | author5=高淑芬&陳劭芊
 | title =注意力不足過動症
 | place =中華民國衛生福利部/心理衛生專輯/03注意力不足過動症.pdf
 | publisher =中華民國衛生福利部
 | series =中華民國衛生福利部/心理衛生專輯
 | volume =1
 | orig-year =June 2015
 | year =
 | month=
 | edition =1
 | chapter =3
 | chapter-url =
 | page =22
 | pages =
 | language =Chinese Traditional, 繁體中文
 | url =https://www.mohw.gov.tw/MOHW_Upload/doc/心理衛生專輯/03注意力不足過動症.pdf
 | archive-url =https://www.mohw.gov.tw/MOHW_Upload/doc/心理衛生專輯/03注意力不足過動症.pdf
 | archive-date =June 2015
 | doi =
 | id =
 | isbn =9789860454154
 | mr =
 | zbl =
 | jfm =
 | quote=atomoxetine，用在病情 較為複雜、或是無法忍受MPH副作用的患者，然而一般發現其對於專注度的改善沒有MPH明顯}}</ref>

而阿托莫西汀與哌甲酯併服的處方尚未經[[美國食品藥物管理局|美國食品藥物管理局]]核可，但醫師會視個案的情況（如共病、預後）以開{{tsl|en|off-label use|仿單標示外使用}}的方式處方之。<ref>{{cite web
 | archive-url =https://www.psychiatry.org/File%20Library/Psychiatrists/Practice/Professional-Topics/Child-Adolescent-Psychiatry/adhd-parents-medication-guide.pdf
 | type= Guidelines (Tertiary source)
 | archive-date=July 2013
 | url= https://www.psychiatry.org/patients-families/adhd/what-is-adhd
 | title =Parent's Medication Guide: ADHD
 | date = July 2013
 | website = American Psychiatric Association
 | publisher = American Psychiatric Association & American Academy of Child and Adolescent Psychiatry (AACAP)
 | access-date = January 2017
 | quote = Though not FDA-approved for combined treatment, atomoxetine (Strattera) is sometimes used in conjunction with stimulants as an off-label combination therapy.}} </ref><ref>{{cite web
 | url= https://medlineplus.gov/ency/article/001551.htm
 | title =Medical Encyclopedia → Attention deficit hyperactivity disorder
 | date =  2017-01-05
 | website = MedlinePlus.gov
 | access-date = January 2017
 | quote = Medicine combined with behavioral treatment often works best. Different ADHD medicines can be used alone or combined with each other. The doctor will decide which medicine is right, based on the person's symptoms and needs.}} </ref><ref name="pmid23560600">{{cite journal
 | author=Treuer T, Gau SS, Méndez L, Montgomery W, Monk JA, Altin M et al.
 | title=A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability. 
 | journal=Journal of Child and Adolescent Psychopharmacology 
 | type= systematic review (Secondary source)
 | year= 2013 
 | volume= 23 
 | issue= 3 
 | pages= 179-93 
 | pmid=23560600 
 | doi=10.1089/cap.2012.0093 
 | pmc=3696926 
 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23560600 
 |quote=Existing evidence suggests, but does not confirm, that this drug combination may benefit some, but not all, patients who have tried several ADHD medications without success. }} </ref><ref name="pmid26364896">{{cite journal 
 | author=Perugi G, Vannucchi G| title=The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder. 
 | journal=Expert Opin Pharmacother 
 | year= 2015 
 | volume= 16 
 | issue= 14 
 | pages= 2193-204 
 | pmid=26364896 
 | doi=10.1517/14656566.2015.1079620 
 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26364896 
 |quote=Although systematic trials on the use of stimulants and ATX in ADHD-BD comorbidity in adulthood are necessary, both treatments should be considered possible options to be carefully evaluated once the patient has been stabilized.}} </ref>在臨床試驗中，並未發現兩者併服後產生加乘的心血管副作用。換言之，兩者併服之心血管副作用，與單獨服用哌甲酯所產生的心血管副作用相同。<ref name="Strattera label_3">{{cite web
 | url = https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=309de576-c318-404a-bc15-660c2b1876fb&type=pdf&name=309de576-c318-404a-bc15-660c2b1876fb
 | type= Leaflet/label (Tertiary source)
 | title = Label of Strattera consisting of atomoxetine
 | date = June 2015
 | website = DailyMed.gov
 | publisher =Eli Lilly Company
 | access-date = February 2017
 | quote =7.7 Methylphenidate\ Coadministration of methylphenidate with STRATTERA did not increase cardiovascular effects beyond those seen with methylphenidate alone. }}</ref>

== 化学 ==
哌甲酯可能有四种同分异构体，因为其分子具有两个手性中心，可分为一对赤式与一对苏式异构体，其中只有右-苏式-哌甲酯有药物活性。当此药刚上市时，以赤式:苏式按3:1混合。赤式非对映异构体也是升压胺。

=== 体液中的检测 ===
哌甲酯及其主要代谢物利他林酸可在血浆、血清或全血中检验，以监测病人是否按医嘱用药，确认可能的中毒者，或协助剂量致命时的法医调查。

== 药物产品 ==
{{see also | 注意力不足過動症#中樞神經刺激劑}}
以下藥品所含之有效成分皆為哌甲酯，各自在[[藥效學|藥效動力學]]上具有相同屬性；在[[藥物代謝動力學|藥物代謝動力學]]上的作用則有些微差異。
* 利他能（Ritalin）<ref>{{cite web
 | url =https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0bf0835-6a2f-4067-a158-8b86c4b0668a
 | title =Label of Ritalin
 | date =January 5, 2017
 | website = DailyMed
 | publisher =Novartis
 | access-date =March, 2017.}}</ref>
* 利長能（Ritalin LA）<ref>{{cite web
 | url =https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/ritalin_la.pdf
 | title =Label of Ritalin LA
 | date =Mid 2015
 | website = Novartis.com
 | publisher =Novartis
 | access-date =January, 2017.}}</ref>
* 專思達（Concerta）<ref name="Concerta's leaflet">
{{cite web
 | url =http://www.concerta.net/pdfs/Prescribing_Info-short.pdf
 | title =Label of Concerta
 | date =2013
 | website =concerta.net
 | publisher =Jassen Cilag
 | access-date =January, 2017.
 | archive-url =https://web.archive.org/web/20170117135801/http://www.concerta.net/pdfs/Prescribing_Info-short.pdf
 | archive-date =2017-01-17
 | dead-url =yes
 }}
</ref>
* 安保美喜錠（Apo-Methylphenidate）<ref name="Apo-Methylphnidate">
{{Citation
 | contribution-url=http://www.fda.gov.tw/MLMS/H0001D.aspx?Type=Lic&LicId=02025016
 | location= Canada
 | title =Information for the patient
 | contribution = 安保美喜錠 10 毫克 衛署藥輸字第 025016 號
 | editor= 鴻汶醫藥實業有限公司
 | author =Apotex Incorporation.
 | date =March 27, 2006
 | year =
 | url =https://www.apotex.com/ca/en/products/downloads/di/0263_PIL.pdf
 | access-date = 2017-03-19}}</ref><ref>
{{Citation
 | location= Canada
 | title =安保美喜錠 10 毫克 衛署藥輸字第 025016 號
 | publisher =Apotex Incorporation.
 | date =March 27, 2006
 | year =
 | url =https://www.apotex.com/ca/en/products/downloads/di/0263_PIL.pdf
 | access-date = 2017-03-19}}</ref>

藥品的劑量應採個人化的方式視患者的反應及需要來決定之。<ref name="new release of Ritalin LA's official guidelines.2017">
{{cite web
 | url =https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=effd952d-ac94-47bb-b107-589a4934dcca
 | title =Label of Ritalin LA
 | date =Mid 2015
 | website = DailyMed.com
 | publisher =Novartis
 | access-date =January, 2017.
 | quote = Dosing Recommendations：Dosage should be individualized according to the needs and responses of the patients.）}}</ref>

===利他能===
有5、 10、 和 20 mg 等三種口服錠劑型。<ref name="availabe doses for Ritalin">{{cite web
 | url =https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0bf0835-6a2f-4067-a158-8b86c4b0668a
 | title =Label of Ritalin
 | date =January 5, 2017
 | website = DailyMed
 | publisher =Novartis
 | access-date =March, 2017.
 | quote=Ritalin hydrochloride, methylphenidate hydrochloride USP, is a mild central nervous system (CNS) stimulant, available as tablets of 5, 10, and 20 mg for oral administration; }}</ref> 

作用時間：約3.5小時。
====藥品說明書（仿單）上的建議劑量====
=====成人建議劑量=====
多數患者的平均劑量為每天總劑量20-30毫克（mg），並在一天中分2-3次達成。建議在餐前30-45分鐘前服用。有些患者的每日<u>總劑量</u>可能需要到達40-60毫克，並在一天中分2-3次達成。除了以上兩者，患者的每日總劑量約控制在10-15 毫克，並在一天中分2-3次達成即可。
<ref name="Ritalin's recommended doses for people with different ages.">
{{cite web
 | url =https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0bf0835-6a2f-4067-a158-8b86c4b0668a
 | title =Label of Ritalin 
 | date = January 5, 2017
 | website = DailyMed.com
 | publisher =Novartis
 | access-date =March, 2017.
 | quote = Dosage should be individualized according to the needs and responses of the patient.
Adults
Tablets: Administer in divided doses 2 or 3 times daily, preferably 30 to 45 minutes before meals. Average dosage is 20 to 30 mg daily. Some patients may require 40 to 60 mg daily. In others, 10 to 15 mg daily will be adequate. Patients who are unable to sleep if medication is taken late in the day should take the last dose before 6 p.m.

SR Tablets: Ritalin-SR tablets have a duration of action of approximately 8 hours. Therefore, Ritalin-SR tablets may be used in place of Ritalin tablets when the 8-hour dosage of Ritalin-SR corresponds to the titrated 8-hour dosage of Ritalin. Ritalin-SR tablets must be swallowed whole and never crushed or chewed.
}}</ref>
=====6-18歲的患者建議劑量=====
起始劑量為分別在早餐和午餐前服用一顆5毫克的利他能。並視需要，以一個星期為一次劑量的調整週期，每次調整的幅度為5或10毫克（mg）。無論分幾次服用，每天的總劑量不建議超過60毫克。
<ref name="Ritalin's recommended doses for children and adolescents.">
{{cite web
 | url =https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0bf0835-6a2f-4067-a158-8b86c4b0668a
 | title =Label of Ritalin 
 | date = January 5, 2017
 | website = DailyMed.com
 | publisher =Novartis
 | access-date =March, 2017.
 | quote = Dosage should be individualized according to the needs and responses of the patient.
Children (6 years and over)
Ritalin should be initiated in small doses, with gradual weekly increments. Daily dosage above 60 mg is not recommended.

If improvement is not observed after appropriate dosage adjustment over a 1-month period, the drug should be discontinued.

Tablets: Start with 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly.

SR Tablets: Ritalin-SR tablets have a duration of action of approximately 8 hours. Therefore, Ritalin-SR tablets may be used in place of Ritalin tablets when the 8-hour dosage of Ritalin-SR corresponds to the titrated 8-hour dosage of Ritalin. Ritalin-SR tablets must be swallowed whole and never crushed or chewed.
}}</ref>

===利長能===
'''利長能'''共有 10、 20、 30、 40和 60 毫克五種劑型，分別與每日服用兩次的短效利他能之5、 10、 15、 20、 和 30 毫克（mg）劑型相對應。<ref name="new release of Ritalin LA's official guidelines.">
{{cite web
 | url =https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=effd952d-ac94-47bb-b107-589a4934dcca
 | title =Label of Ritalin LA
 | date =Mid 2015
 | website = DailyMed.com
 | publisher =Novartis
 | access-date =January, 2017.
 | quote = Methylphenidate hydrochloride is a central nervous system (CNS) stimulant.
Ritalin LA® (methylphenidate hydrochloride) extended-release capsules is an extended-release formulation of methylphenidate with a bi-modal release profile. Ritalin LA uses the proprietary SODAS® (Spheroidal Oral Drug Absorption System) technology. Each bead-filled Ritalin LA capsule contains half the dose as immediate-release beads and half as enteric-coated, delayed-release beads, thus providing an immediate release of methylphenidate and a second delayed release of methylphenidate. Ritalin LA 10, 20, 30, 40, and 60 mg capsules provide in a single dose the same amount of methylphenidate as dosages of 5, 10, 15, 20, or 30 mg of Ritalin tablets given b.i.d.）}}</ref>

====藥品說明書上的建議劑量====
建議起始劑量為每天一粒20毫克的利長能。然而醫師可依照臨床判斷將起始劑量降至每天一粒 10毫克的利長能。往後的日子中，劑量的調整建議以一周調整10毫克（mg）為準。利長能的劑量可依照患者對藥物的耐受性及症狀改善的程度將劑量以一周調整10毫克的準則，逐漸調整至每天一粒60毫克的利長能。然而不建議將劑量繼續增加到超過60毫克/每天。
<ref name="new release of Ritalin LA's official guidelines.2017 in respect of recommended initial dose.">
{{cite web
 | url =https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=effd952d-ac94-47bb-b107-589a4934dcca
 | title =Label of Ritalin LA
 | date =Mid 2015
 | website = DailyMed.com
 | publisher =Novartis
 | access-date =January, 2017.
 | quote = Initial Treatment
The recommended starting dose of Ritalin LA is 20 mg once daily. Dosage may be adjusted in weekly 10 mg increments to a maximum of 60 mg/day taken once daily in the morning, depending on tolerability and degree of efficacy observed. Daily dosage above 60 mg is not recommended. When in the judgement of the clinician a lower initial dose is appropriate, patients may begin treatment with Ritalin LA 10 mg.）}}</ref>

藥效作用時間：約8小時。
====短效藥物轉換至長效利長能（Ritalin LA）的劑量轉換建議表====
{| class="wikitable"
|-
! （Previous Methylphenidate Dose） !! （Recommended Ritalin LA Dose）
|-
| 每天服用5毫克的利他能二次 ||每天一粒10毫克的利長能 （10 mg q.d.）
|-
| 每天服用10毫克的利他能二次或20mg的methylphenidate-SR || 每天一粒20毫克的利長能（20 mg q.d.）
|-
| 每天服用15毫克的利他能二次 ||每天一粒30毫克的利長能 （30 mg q.d.）
|-
| 每天服用20毫克的利他能二次或40mg的methylphenidate-SR || 每天一粒40毫克的利長能（40 mg q.d.）
|-
| 每天服用30毫克的利他能二次或60mg的methylphenidate-SR || 每天一粒60毫克的利長能（60 mg q.d.）
|}
<ref name="new release of Ritalin LA's official guidelines.2017 Dose conversion from Ritalin to Ritalin LA.">
{{cite web
 | url =https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=effd952d-ac94-47bb-b107-589a4934dcca
 | title =Label of Ritalin LA
 | date =Mid 2015
 | website = DailyMed.com
 | publisher =Novartis
 | access-date =January, 2017.
 | quote = Initial Treatment
The recommended starting dose of Ritalin LA is 20 mg once daily. Dosage may be adjusted in weekly 10 mg increments to a maximum of 60 mg/day taken once daily in the morning, depending on tolerability and degree of efficacy observed. Daily dosage above 60 mg is not recommended. When in the judgement of the clinician a lower initial dose is appropriate, patients may begin treatment with Ritalin LA 10 mg.）}}</ref>
===專思達===
{{main|專注達}}
藥效持續時間：約十二小時。
<ref name="Concerta's official guidance">{{cite web
 | url =https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a88218c-5b18-4220-8f56-526de1a276cd
 | title =Label of Concerta
 | date =2013
 | website = DailyMed.gov
 | publisher =Jassen Cilag
 | access-date =January, 2017.
 | quote= 1 INDICATIONS AND USAGE \ 
CONCERTA® is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children 6 years of age and older, adolescents, and adults up to the age of 65 [see CLINICAL STUDIES (14)]. 

A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; "on the go;" excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met.}}</ref> 

====藥品說明書上的建議劑量====
{| class="wikitable sortable"
|-
! 患者年紀 !! 建議起始劑量 !!劑量範圍
|-
| 6-12歲 || 18 毫克/每天 ||18 - 54 毫克/每天 
|-
| 13-17歲  || 18 毫克/每天 ||18 - 72 毫克/每天 每天每公斤不可超過2毫克。{{NoteTag|name=|1=舉例：一個三十公斤的服藥者每天不可服用超過60毫克的專思達}}
|-
| 18-65歲  || 18 毫克/每天  ||18 - 72 毫克/每天 
|}
<ref name="Concerta's leaflet"/>
註解：
# 在專思達的藥物試驗過程中發現，13-17歲的青年試驗組中，專思達的最低有效劑量為： 每天每公斤1.4毫克。<ref name="Concerta's clinical trial for adolescent">
{{cite web
 | url =https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a88218c-5b18-4220-8f56-526de1a276cd
 | title =Label of Concerta
 | date =2013
 | website = DailyMed.gov
 | publisher =Jassen Cilag
 | access-date =January, 2017.
 | quote= 14.2 Adolescents
In a randomized, double-blind, multicenter, placebo-controlled trial (Study 4) involving 177 patients, CONCERTA® was demonstrated to be effective in the treatment of ADHD in adolescents aged 13 to 18 years at doses up to 72 mg/day (1.4 mg/kg/day). Of 220 patients who entered an open 4-week titration phase, 177 were titrated to an individualized dose (maximum of 72 mg/day) based on meeting specific improvement criteria on the ADHD Rating Scale and the Global Assessment of Effectiveness with acceptable tolerability. Patients who met these criteria were then randomized to receive either their individualized dose of CONCERTA® (18 – 72 mg/day, n=87) or placebo (n=90) during a two-week double-blind phase. At the end of this phase, mean scores for the investigator rating on the ADHD Rating Scale demonstrated that CONCERTA® was statistically significantly superior to placebo.}}</ref>
# 18歲以上的兩個成人試驗組中，發現每天18-72毫克的劑量皆可達到在統計學上具顯著意義的療效，然而以每天36毫克以上進而達到統計學上具顯著意義的療效的臨床試驗者為大多數。
<ref name="Concerta's clinical trials for people older than 18">
{{cite web
 | url =https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a88218c-5b18-4220-8f56-526de1a276cd
 | title =Label of Concerta
 | date =2013
 | website = DailyMed.gov
 | publisher =Jassen Cilag
 | access-date =January, 2017.
 | quote= 14.2 Adolescents
14.3 Adults
Two double-blind, placebo-controlled studies were conducted in 627 adults aged 18 to 65 years. The controlled studies compared CONCERTA® administered once daily and placebo in a multicenter, parallel-group, 7-week dose-titration study (Study 5) (36 to 108 mg/day) and in a multicenter, parallel-group, 5-week, fixed-dose study (Study 6) (18, 36, and 72 mg/day).

Study 5 demonstrated the effectiveness of CONCERTA® in the treatment of ADHD in adults aged 18 to 65 years at doses from 36 mg/day to 108 mg/day based on the change from baseline to final study visit on the Adult ADHD Investigator Rating Scale (AISRS). Of 226 patients who entered the 7-week trial, 110 were randomized to CONCERTA® and 116 were randomized to placebo. Treatment was initiated at 36 mg/day and patients continued with incremental increases of 18 mg/day (36 to 108 mg/day) based on meeting specific improvement criteria with acceptable tolerability. At the final study visit, mean change scores (LS Mean, SEM) for the investigator rating on the AISRS demonstrated that CONCERTA® was statistically significantly superior to placebo.

Study 6 was a multicenter, double-blind, randomized, placebo-controlled, parallel-group, dose-response study (5-week duration) with 3 fixed-dose groups (18, 36, and 72 mg). Patients were randomized to receive CONCERTA® administered at doses of 18 mg (n=101), 36 mg (n=102), 72 mg/day (n=102), or placebo (n=96). All three doses of CONCERTA® were statistically significantly more effective than placebo in improving CAARS (Conners' Adult ADHD Rating Scale) total scores at double-blind end point in adult subjects with ADHD.}}</ref>
====短效藥物轉換至長效專思達的劑量轉換建議表====
{| class="wikitable sortable"
|-
! 短效利他能的每天總劑量  !! 建議轉換至專思達的劑量
|-
| 每天服用5毫克的利他能二至三次 || 每天早上服用一顆18毫克的專思達
|-
| 每天服用10毫克的利他能二至三次 ||每天早上服用一顆36毫克的專思達
|-
| 每天服用15毫克的利他能二至三次 || 每天早上服用一顆54毫克的專思達
|-
| 每天服用20毫克的利他能二至三次 || 每天早上服用一顆72毫克的專思達
|}<ref name="Concerta's leaflet"/>
註解：
# 台灣尚未引進72毫克之專思達。

===安保美喜錠===
安保美喜錠（Apo-Methylphenidate）為利他能的副廠藥品。 副廠名：Apotex Incorporation. <ref name="Apo-Methylphnidate"/>
===維持療法===
患者所需的藥物治療時間因人而異。然而學界普遍認為，藥物治療通常不能太短。患者與醫師應該定期追蹤自己以及患者的病況。患者的症狀有可能在暫時或永久停藥後繼續改善，倘若如此，則可能是停藥時機點。
<ref name="new release of Ritalin LA's official guidelines.2017 in respect of recommended maintenance dose.">
{{cite web
 | url =https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=effd952d-ac94-47bb-b107-589a4934dcca
 | title =Label of Ritalin LA
 | date =Mid 2015
 | website = DailyMed.com
 | publisher =Novartis
 | access-date =January, 2017.
 | quote = Maintenance/Extended Treatment\There is no body of evidence available from controlled trials to indicate how long the patient with ADHD should be treated with Ritalin LA. It is generally agreed, however, that pharmacological treatment of ADHD may be needed for extended periods. Nevertheless, the physician who elects to use Ritalin LA for extended periods in patients with ADHD should periodically re-evaluate the long-term usefulness of the drug for the individual patient with trials off medication to assess the patient’s functioning without pharmacotherapy. Improvement may be sustained when the drug is either temporarily or permanently discontinued.）}}</ref>

== 历史、社会与文化 ==

=== 法律状态 ===
* 在全球范围内，哌甲酯是《[[精神药物公约|精神药物公约]]》中的Schedule II类药物。
* 在美国，哌甲酯被分类为Schedule II管制物质，即有公认的医疗价值但具有高的滥用可能性。
* 在英国，哌甲酯是B类受管制物质。无处方而持有哌甲酯可处以最高五年有期徒刑和/或无上限的罚款，非法售卖可处以最高14年有期徒刑和/或无上限的罚款。
* 在加拿大，哌甲酯被列入《[[管制药物与物质法|管制药物与物质法]]》中的Schedule III（与LSD、迷幻蘑菇、酶斯卡灵等同一分类），且无处方持有哌甲酯为非法。
* 在新西兰，哌甲酯是B2类管制物质，非法持有可处以六个月有期徒刑，非法出售可处以14年有期徒刑。
* 在澳大利亚，哌甲酯是Schedule 8管制物质。此类物质在出售前必须放置在可上锁的保险箱内，无处方持有可被处以巨额罚款甚至监禁。
* 在瑞典，哌甲酯是List II类管制物质，具有公认的医疗价值。无处方持有可被处以最高三年的有期徒刑。
* 在法国，哌甲酯被分类为麻醉剂，开处方与售卖被严格管制，只能在开出处方的医院购买（hospital-only prescription），用于初次治疗以及每年一度的咨询。
* 在印度，哌甲酯是Schedule X药物且受1945年发布的《药物与化妆品法案》管制，只能凭神经病专家或精神科医生开出的处方购买。
* 在台湾，哌甲酯依例为第三级管制药品，医师处方需使用管制药品专用处方笺。<ref>[http://www.fda.gov.tw/TC/includes/GetFile.ashx?id=1100&chk=b105df22-6bda-473c-8da8-ae0e84d703b3&mid=46&name=fdContent 管制藥品分級及品項]</ref>
* 在[[中华人民共和国|中华人民共和国]]，这一药物属于第一类精神药品，<ref>{{cite web|title=精神药品品种目录（2007年版）|url=http://news.pharmnet.com.cn/news/2007/10/31/211646.html|author=国家食品药品监督管理局|publisher=医药网|date=2007-10-31|accessdate=2013-02-04}}</ref>管制措施与其他精神兴奋剂（如苯丙胺和莫达非尼）相同。不过不同于其他第一类精神药品和麻醉药品的是，哌甲酯控缓释制剂用于治疗儿童[[注意力不足過動症|注意缺陷多动障碍]]，可一次处方15日量（而非一般精麻药品控缓释制剂的7日量）。<ref>{{Cite web|url=http://www.gov.cn/flfg/2007-03/13/content_549406.htm|title=处方管理办法（原卫生部令第53号）|accessdate=|author=|date=2007-03-13|publisher=中国政府网}}</ref>

==註解==
{{noteFoot}}

==延伸閱讀==
* [[注意力不足過動症|注意力不足過動症]]
* [[嗜睡症|嗜睡症]]

=== 參考資料 ===

<div style = "height:800px; overflow:auto; padding:3px; border:1px solid #aaa;">

{{Reflist|2}}

</div>
{{-}}
{{Antiobesity preparations}}
{{Aphrodisiacs}}
{{Euphoriants}}
{{Sigmaergics}}
{{ADHD_pharmacotherapies}}
[[Category:苯乙胺类|Category:苯乙胺类]]
[[Category:拟交感神经药|Category:拟交感神经药]]
[[Category:兴奋剂|Category:兴奋剂]]
[[Category:哌啶|Category:哌啶]]
[[Category:羧酸酯|Category:羧酸酯]]
[[Category:芳香化合物|Category:芳香化合物]]
[[Category:甲酯|Category:甲酯]]
[[Category:去甲肾上腺素-多巴胺重摄取抑制剂|Category:去甲肾上腺素-多巴胺重摄取抑制剂]]